心房颤动的一级预防：2012年我们进展到哪一步了？
Primary Prevention of Atrial Fibrillation where are we in 2012?
作者信息
Imazio Massimo
机构信息
Cardiology Department, Maria Vittoria Hospital, Torino, Italy.
出版信息
J Atr Fibrillation. 2012 Aug 20;5(2):608. doi: 10.4022/jafib.608. eCollection 2012 Aug-Sep.
Abstract
Drugs to alter or delay myocardial remodelling associated with heart failure, hypertension, or inflammation in the post-operative setting, may prevent the development of atrial fibrillation. Current experimental and clinical evidences support specific treatments for defined patient population (i.e. ACE-inhibitors and ARB for chronic heart failure and hypertension expecially with LV hypertrophy; statins, corticosteroids and possibly colchicine after cardiac surgery).
摘要
在术后环境中，用于改变或延缓与心力衰竭、高血压或炎症相关的心肌重塑的药物，可能会预防房颤的发生。目前的实验和临床证据支持针对特定患者群体的特定治疗方法（即用于慢性心力衰竭和高血压尤其是伴有左心室肥厚的患者的ACE抑制剂和ARB；心脏手术后使用他汀类药物、皮质类固醇以及可能的秋水仙碱）。
相似文献
1
Primary Prevention of Atrial Fibrillation where are we in 2012?心房颤动的一级预防：2012年我们进展到哪一步了？
J Atr Fibrillation. 2012 Aug 20;5(2):608. doi: 10.4022/jafib.608. eCollection 2012 Aug-Sep.
2
Role of angiotensin-converting enzyme inhibitors, angiotensin II receptor blockers, and aldosterone antagonists in the prevention of atrial and ventricular arrhythmias.血管紧张素转换酶抑制剂、血管紧张素II受体阻滞剂和醛固酮拮抗剂在预防房性和室性心律失常中的作用。
Pharmacotherapy. 2009 Jan;29(1):31-48. doi: 10.1592/phco.29.1.31.
3
Upstream therapies for management of atrial fibrillation: review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: primary prevention.心房颤动管理的上游治疗：临床证据回顾及其对欧洲心脏病学会指南的影响。第一部分：一级预防。
Europace. 2011 Mar;13(3):308-28. doi: 10.1093/europace/eur002.
4
Effect of angiotensin-converting enzyme inhibitors or angiotensin receptor blockers on the frequency of post-cardiothoracic surgery atrial fibrillation.血管紧张素转换酶抑制剂或血管紧张素受体阻滞剂对心胸外科手术后房颤发生率的影响。
Ann Pharmacother. 2007 Mar;41(3):433-7. doi: 10.1345/aph.1H583. Epub 2007 Mar 6.
5
[Upstream therapy for atrial fibrillation].[心房颤动的上游治疗]
Nihon Rinsho. 2013 Jan;71(1):86-90.
6
Role of the renin-angiotensin-aldosterone system in atrial fibrillation and cardiac remodeling.肾素-血管紧张素-醛固酮系统在心房颤动及心脏重塑中的作用
Curr Opin Cardiol. 2005 Jan;20(1):31-7.
7
Colchicine for primary prevention of atrial fibrillation after open-heart surgery: Systematic review and meta-analysis.秋水仙碱用于心脏直视手术后的心房颤动一级预防：系统评价和荟萃分析。
Int J Cardiol. 2017 Dec 15;249:127-137. doi: 10.1016/j.ijcard.2017.08.039. Epub 2017 Sep 1.
8
Prevention of atrial fibrillation with angiotensin-converting enzyme inhibitors and angiotensin receptor blockers: a meta-analysis.血管紧张素转换酶抑制剂和血管紧张素受体阻滞剂预防心房颤动：一项荟萃分析。
J Am Coll Cardiol. 2005 Jun 7;45(11):1832-9. doi: 10.1016/j.jacc.2004.11.070.
9
Drug Insight: angiotensin-converting-enzyme inhibitors and atrial fibrillation--indications and contraindications.药物洞察：血管紧张素转换酶抑制剂与心房颤动——适应证与禁忌证
Nat Clin Pract Cardiovasc Med. 2006 Apr;3(4):220-5. doi: 10.1038/ncpcardio0480.
10
Rationale and design of the COlchicine for Prevention of the Post-pericardiotomy Syndrome and Post-operative Atrial Fibrillation (COPPS-2 trial): a randomized, placebo-controlled, multicenter study on the use of colchicine for the primary prevention of the postpericardiotomy syndrome, postoperative effusions, and postoperative atrial fibrillation.COlchicine 用于预防心包切开术后综合征和术后心房颤动（COPPS-2 试验）的原理和设计：一项关于预防性使用秋水仙碱预防心包切开术后综合征、术后积液和术后心房颤动的随机、安慰剂对照、多中心研究。
Am Heart J. 2013 Jul;166(1):13-9. doi: 10.1016/j.ahj.2013.03.025. Epub 2013 May 6.
引用本文的文献
1
Cardiovascular medications used for comorbid diseases in patients with atrial fibrillation. The JoFib study.用于房颤合并症患者的心血管药物。JoFib 研究。
Eur J Clin Pharmacol. 2024 Apr;80(4):545-552. doi: 10.1007/s00228-024-03622-8. Epub 2024 Jan 23.
本文引用的文献
1
Preoperative statin therapy for patients undergoing cardiac surgery.心脏手术患者的术前他汀类药物治疗。
Cochrane Database Syst Rev. 2012 Apr 18(4):CD008493. doi: 10.1002/14651858.CD008493.pub2.
2
The post-pericardiotomy syndrome.心包切开后综合征。
Curr Opin Pulm Med. 2012 Jul;18(4):366-74. doi: 10.1097/MCP.0b013e32835311a2.
3
Efficacy and safety of colchicine for pericarditis prevention. Systematic review and meta-analysis.秋水仙碱预防心包炎的疗效和安全性。系统评价和荟萃分析。
Heart. 2012 Jul;98(14):1078-82. doi: 10.1136/heartjnl-2011-301306. Epub 2012 Mar 22.
4
A review of the cost of atrial fibrillation.心房颤动的成本回顾。
Value Health. 2012 Mar-Apr;15(2):240-8. doi: 10.1016/j.jval.2011.09.009. Epub 2011 Dec 15.
5
Blockade of the renin-angiotensin-aldosterone system (RAAS) for primary prevention of non-valvular atrial fibrillation: a systematic review and meta analysis of randomized controlled trials.阻断肾素-血管紧张素-醛固酮系统（RAAS）用于非瓣膜性心房颤动的一级预防：随机对照试验的系统评价和荟萃分析。
Int J Cardiol. 2013 Apr 30;165(1):17-24. doi: 10.1016/j.ijcard.2012.02.009. Epub 2012 Mar 14.
6
Medical treatment of atrial fibrillation.心房颤动的治疗。
J Cardiovasc Med (Hagerstown). 2012 Feb;13(2):97-107. doi: 10.2459/JCM.0b013e32834f23e1.
7
Atrial fibrillation: Colchicine lowers postoperative AF risk.
Nat Rev Cardiol. 2011 Dec 6;9(2):67. doi: 10.1038/nrcardio.2011.196.
8
Colchicine for the prevention of postoperative atrial fibrillation: a new indication for a very old drug?秋水仙碱预防术后心房颤动：一种古老药物的新适应症？
Circulation. 2011 Nov 22;124(21):2281-2. doi: 10.1161/CIRCULATIONAHA.111.057075.
9
Colchicine reduces postoperative atrial fibrillation: results of the Colchicine for the Prevention of the Postpericardiotomy Syndrome (COPPS) atrial fibrillation substudy.秋水仙碱可减少术后心房颤动：秋水仙碱预防心包切开术后综合征（COPPS）心房颤动亚研究的结果。
Circulation. 2011 Nov 22;124(21):2290-5. doi: 10.1161/CIRCULATIONAHA.111.026153. Epub 2011 Nov 16.
10
Colchicine prevents early postoperative pericardial and pleural effusions.秋水仙碱可预防术后早期心包和胸腔积液。
Am Heart J. 2011 Sep;162(3):527-32.e1. doi: 10.1016/j.ahj.2011.05.017. Epub 2011 Jul 18.
Zotero 插件